Poor Response to Monoclonal Therapy in Asthma
Research type
Research Study
Full title
Investigating Poor Response to Monoclonal Therapy in Asthma
IRAS ID
241052
Contact name
Dominick Shaw
Contact email
Sponsor organisation
University of Nottingham
Duration of Study in the UK
2 years, 4 months, 31 days
Research summary
Research Summary
Asthma affects 8% of the entire population. 4-5% of asthma sufferers have severe asthma, characterised by recurrent exacerbations (worsening of symptoms leading to the person having a bout of corticosteroids and/or antibiotics), significant symptoms and lack of response to the most widely used therapy, corticosteroids.There is now a new type of treatment (an antibody drug) which is licensed to manage severe asthma called Mepolizumab (anti-IL5 treatment). There is evidence Mepolizumab and other similar antibody drugs are effective at reducing asthma exacerbations and reduce the need for oral corticosteroids for those that have severe asthma.
However, some patients respond poorly to Mepolizumab and we would like to find out why this hapapens. It is hoped that we can identify the mechanism of poor treatment response to Mepolizumab. It is also hoped that we can understand why symptoms worsen to the point of requiring antibiotics and/or steroids (also known as an exacerbation) for those prescribed Mepolizumab.
Summary of Results
The Proclaim Study has completed all follow-up visits and have undergone data cleaning and validation of data processes.We are now putting together all the researching findings to help us understand how to apply our results into clinical practice that will have the biggest impact on patient care.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
18/EM/0268
Date of REC Opinion
9 Nov 2018
REC opinion
Further Information Favourable Opinion